Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | SIRT6 | Q8N6T7 | 4/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772717 | 0.83 | MAPT (0.72) | LMNAMAPTSIRT6RECQLHTR7 | |
| SCHEMBL31306580 | 0.82 | MAPT (0.71) | LMNAMAPTSIRT6RECQLHTR7 | |
| SCHEMBL13548702 | 0.81 | GAA (0.49) | LMNAMAPTSIRT6RECQLL3MBTL1 | |
| SCHEMBL2553773 | 0.81 | MAPT (0.69) | LMNAMAPTSIRT6RECQLHTR7 | |
| SCHEMBL4256259 | 0.80 | LMNA (0.64) | LMNAMAPTSIRT6RECQLHTR7 | |
| SCHEMBL30059159 | 0.79 | LMNA (1.00) | LMNAMAPTSIRT6RECQLL3MBTL1 | |
| SCHEMBL25877527 | 0.79 | LMNA (0.94) | LMNAMAPTSIRT6RECQLL3MBTL1 | |
| SCHEMBL3109069 | 0.79 | LMNA (1.00) | LMNAMAPTSIRT6RECQLL3MBTL1 | |
| SCHEMBL2553652 | 0.79 | MAPT (0.70) | LMNAMAPTSIRT6RECQLHTR7 | |
| SCHEMBL24195921 | 0.78 | HTR6 (0.44) | LMNAMAPTRECQLL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691970-B2 | Pyrazolopyridinone compounds | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| EP-3713941-B1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2022-06-22 | — | — | EP | disclosed |
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-20 | — | — | US | disclosed |
| EP-3713941-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | Janssen Pharmaceutica NV (BE) | 2020-09-30 | — | — | EP | disclosed |
| WO-2019101182-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-31 | — | — | WO | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | LMNA 2670/4885MAPT 19/4885SIRT6 4196/4885 |
| US-20210147411-A1 | PYRAZOLOPYRIDINONE COMPOUNDS | FGFR1, FGFR3, FGFR2 | LMNA 4095/4885MAPT 1516/4885SIRT6 2510/4885 |
| US-11691970-B2 | Pyrazolopyridinone compounds | FGFR1, FGFR3, FGFR2 | LMNA 4095/4885MAPT 1516/4885SIRT6 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.